The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.
The two-year contract will be used to develop a portable prototype to quickly identify critical infectious pathogens considered threatening to war combatants.
The consortium aims to identify tuberculosis protein targets and corresponding small molecule inhibitors that can be used to develop drugs to shorten therapy duration.
The study aims to explore the "unique benefits and challenges" or incorporating genomic information into the routine care of active duty Air Force members.
The study being conducted under the Genomes2People umbrella will explore how best to introduce genetic information into the routine care of active duty service members.
Bioinformatics firm Berg is combining multi-omics data from the Department of Defense's Center for Prostate Disease Research in search of biomarkers.
The funding will go toward completing the development of the company's point-of-care platform for distinguishing bacterial from viral infections.
The funding will advance work focused on the discovery of a genomic configuration that correlates to chemotherapy sensitivity.
It was a rough year for biotech stocks — the Nasdaq Biotech Index fell 22 percent even as the Dow gained 13 percent and the Nasdaq gained 8 percent.
The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.
The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.
Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.
In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.